Navigation Links
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Date:10/12/2008

th whom we have established a very productive collaboration. The results of the present study reconfirm our interest in the target and provide for new product opportunities within our expanding siRNA product pipeline. Quark has the deepest clinical-stage pipeline of siRNAs under development, with efficacy studies completed for several compounds, many stemming from our internal gene discovery programs, and ongoing research efforts to further broaden our range of siRNA product candidates."

Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, principal investigator of the study said, "RNAi-mediated reduction of Nrf2 expression represents a potential breakthrough for treating non-small cell lung cancer. Suppression of Nrf2 effectively inhibited tumor growth and increased sensitivity to chemotherapeutic drug-induced cell death in the study. It is critical that we establish new and effective therapies for NSCLC, which is intrinsically resistant and generally nonresponsive to initial chemotherapy, and commonly leads to acquired resistance even as therapies become increasingly sophisticated. We are encouraged by Quark's continued evaluation and development of therapeutics that target Nrf2 to inhibit tumor growth and circumvent chemoresistance."

Quark Pharmaceuticals has recently announced QPI-1007, its first drug candidate to utilize a novel siRNA structure developed by Quark with freedom to operate in the siRNA intellectual property space. QPI-1007 is currently being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases.

The publication can be seen online at http://cancerres.aacrjournals.org/cgi/content/abstract/68/19/7975.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical compan
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... ALEXANDRIA, Va. , May 20, 2013   ... B. Douglas Hoey , RPh, MBA issued the ... Hart Research Associates regarding Medicare Part D "preferred ... pharmacies from offering patients the plan,s lowest advertised co-payments: ... "Officials with Medicare and MedPAC , ...
(Date:5/20/2013)... MAPLE GROVE, Minn. , May 20, 2013 ... committed to the development of new treatments for ... the launch of its newly designed website, ... through images and narratives.  As part of the ... – our new branding campaign centers around people ...
(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...
Breaking Medicine Technology:Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Upsher-Smith Introduces Newly Redesigned Corporate Website 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3
... 8, 2012 /PRNewswire-Asia / -- WuXi PharmaTech (Cayman) Inc. ... and medical device R&D outsourcing company with operations in ... will release financial results for the fourth quarter of ... Thursday, March 8, 2012 (which will be Friday morning, ...
... SACRAMENTO, Calif., Feb. 7, 2012 Sutter Medical Center, ... nation and the first in California to receive full ... Centers (SCPC). The announcement comes as the nation ushers in ... is the most common cardiac arrhythmia that can lead ...
Cached Medicine Technology:WuXi PharmaTech Schedules Fourth-Quarter 2011 Earnings Release 2Sutter Medical Center First in California to Receive Atrial Fibrillation Certification 2
(Date:5/20/2013)... 2013) - A new "telerehabilitation" approach lets physical therapists ... Internet, with good accuracy compared with face-to-face examinations, reports ... Spine . The journal is published ... of Wolters Kluwer Health . , Taking advantage ... a more feasible alternative to in-person clinic visits, according ...
(Date:5/20/2013)... May 20, 2013 Medicare Part D ... satisfied, citing lower costs, convenient access to pharmacies and ... Research Associates released today by the Pharmaceutical Care Management ... (9.5 million) are currently enrolled in plans with preferred ... and overall value of plans with preferred pharmacy networks,” ...
(Date:5/20/2013)... 2013 Cliff Lake Dental Care is pleased to ... schedules when visiting the dentist office . The change was ... schedule. , Here are the new office hours: Mondays- 8 a.m. ... 8 a.m. to 1 p.m. and 2-5 p.m., Thursdays 7 a.m. ... will be open to take appointments only. Cliff Lake Dental wants ...
(Date:5/20/2013)... 20, 2013 A pioneer and ... solutions, i2i Systems announced today that ... Foundation (SCF) selected i2iTracks as their population management ... meet their Meaningful Use (MU), Government Performance and ... requirements – a welcomed solution to managing the ...
(Date:5/20/2013)... May 20, 2013 Selexis SA, a ... identification and cell line development for scale-up and manufacturing ... co-founder will present data on the Company’s core technology ... Engineering Conference, May 20 - 23 at the Hyatt ... Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, ...
Breaking Medicine News(10 mins):Health News:Telerehabilitation allows accurate assessment of patients with low back pain 2Health News:Telerehabilitation allows accurate assessment of patients with low back pain 3Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Cliff Lake Dental Care Announces Office Hours Change 2Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 2Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 3Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
... new but today there is a growing industry catering to ... National Guard Sgt. Darrell "J.R." Salzman has learned to tie ... shiny metal hook that serves as his right called Utah ... myoelectric Utah Arm, made by Motion Control Inc., of Salt ...
... number of doctors in Portugal were refusing to carry out ... the 10th week of pregnancy . ,The law ... at least nine public hospitals out of a total of ... approved the law in March after a February referendum found ...
... Asbestos Saskatchewan committee, the Canadian Cancer Society's call for a ... is welcomed news and reflects a changing environment. ,"Obviously ... Canada of public interests and social justice organizations to put ... political agenda, Sass was quoted.,"Up to now it has not ...
... will build a 60-acre health and education complex in Islamabad ... people of the capital and the twin city of Rawalpindi ... residential development plan to develop a Health and Education City ... colleges of medicine, nursing, and dentistry. ,Harvard ...
... A new study has found that divorce, not shared genetic ... to the higher rates of break-ups experienced by the offspring ... study to look at genetics as a reason in the ... found that the parents' divorce itself, played a key role ...
... of children ages 5 to 7,C-reactive protein, a marker ... disease, may also indicate cognitive impairment in children ... OSA have increased levels of hsCRP [high-sensitivty C-reactive protein] ... David Gozal, M.D., of the University of Louisville in ...
Cached Medicine News:Health News:War Stimulates Research Blitz in Prosthetics Industry 2Health News:Move To Ban Asbestos Welcomed 2Health News:Genetics is Not the Reason for Family Break-ups 2Health News:C -reactive Protein is the Marker for Cardiovascular Disease 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: